IN the patients after oral anticoagulant therapy INR can reflect the result of PT more exactly.
患者口服抗凝治疗后仅INR能较准确地反映PT的结果。
International Circulation: In oral anticoagulant therapy, how can we make the balance between safety and efficacy?
《国际循环》：关于口服抗凝药治疗，我们如何保持安全性和有效性之间的平衡？
Warfarin a synthesized version of dicumarol is5to10times stronger than the original compound and is the most commonly used oral anticoagulant.
华法令是目前最常用的此类药物，它是一种合成的双香豆素类，比天然复合物强5-10倍。
Moreover, although lab monitoring with oral anticoagulant may not be necessary, antidotes of such compounds still need to be developed and tested for their efficacy.
此外，尽管口服抗凝药的实验监测也许并无必要，但还需开发这类药物的解毒剂并对其效果加以检测。
We aimed to identify the strongest predictors of VTE recurrence after discontinuation of oral anticoagulant therapy in a population of both provoked and unprovoked patients.
本研究旨在针对触发和非触发人群，当终止口服抗凝药物治疗后，探究如何识别VTE复发的最强预测因子。
We now have new oral anticoagulants that can be given in fixed doses, produce a consistent and predictable anticoagulant response and don't require routine coagulation monitoring.
我们现在有固定的给药剂量、产生一致且可预测的抗凝反应且无需常规监测的新口服抗凝药物。
Ximelagatran is a new oral anticoagulant. This article introduces the pharmacodynamic and pharmacokinetic properties of ximelagatran and gives a brief description of some relevant clinical trials.
希美加群是一种新型的口服抗凝剂。现就希美加群的药代学和药动学特性以及围绕其进行的一些临床试验进行简单介绍。
Ximelagatran is a new oral anticoagulant. This article introduces the pharmacodynamic and pharmacokinetic properties of ximelagatran and gives a brief description of some relevant clinical trials.
希美加群是一种新型的口服抗凝剂。现就希美加群的药代学和药动学特性以及围绕其进行的一些临床试验进行简单介绍。
应用推荐